What is Immunome's EBITDA?

Immunome (IMNM) reported EBITDA of -$58.73M in Q1 2026.

How has Immunome's EBITDA changed year-over-year?

Immunome's EBITDA decreased by 33.4% year-over-year, from -$44.03M to -$58.73M.

What is the long-term trend for Immunome's EBITDA?

Over 4 years (2021 to 2025), Immunome's EBITDA has grown at a 73.5% compound annual growth rate (CAGR), from -$24.45M to -$221.65M.

What does EBITDA mean?

Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.

Immunome IMNM EBITDA

EBITDA at other companies

Arcus BiosciencesRCUS

-$132M-10.9%

SELLAS Life Sciences Group, Inc.SLS

-$8.11M—

ArriVent BioPharma, Inc.AVBP

-$46.67M+30.9%

IDEAYA Biosciences, Inc.IDYA

-$107.86M-28.7%

PfizerPFE

——

ImmunityBio, Inc.IBRX

——

Other financials

Income statement

See full

Revenue--100%

Operating income-$59.3M-32.9%

Net income-$53.8M-29.3%

EPS (diluted)-$0.48+7.7%

Balance sheet

See full

Cash & equivalents$582.7M+126%

Total debt$3.7M-22.6%

Total equity$588.7M+91.7%

Total assets$619.8M+80.9%

Cash flow

See full

Operating cash flow-$58.6M-10.5%

CapEx$3.0M-18.1%

Free cash flow-$61.6M-8.7%

Valuation

See full

Market cap$2.19B+323%

Enterprise value$1.61B+470%

P/S545.2×+498×

Profitability

See full

Operating margin-5,947.9%-12,002pp

Net margin-5,593.8%-11,284pp

FCF margin-5,118.9%-8,601pp

Returns & leverage

See full

Return on equity-50.1%-10.8pp

Debt / equity0×0.0×

Current ratio21.7×+11.2×

Where this comes from

Calculated from Immunome’s reported figures.

−$59.3Mebit+

$603.0KDepreciation Depletion & Amortization

=-$58.73M

The official record: Immunome’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immunome's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Immunome's EBITDA?: Immunome (IMNM) reported EBITDA of -$58.73M in Q1 2026.
How has Immunome's EBITDA changed year-over-year?: Immunome's EBITDA decreased by 33.4% year-over-year, from -$44.03M to -$58.73M.
What is the long-term trend for Immunome's EBITDA?: Over 4 years (2021 to 2025), Immunome's EBITDA has grown at a 73.5% compound annual growth rate (CAGR), from -$24.45M to -$221.65M.
What does EBITDA mean?: Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.